Industry News

The investment aims to build local oral drug manufacturing capacity and support production of the investigational GLP-1 therapy orforglipron.

The collaboration supports controlled human infection model studies aimed at accelerating RSV vaccine development.

The project will expand plasma-derived therapy production capacity and add at least 300 jobs at the company’s Kankakee manufacturing site.

The extended agreement will increase manufacturing capacity in Houston to support demand for the approved Zynteglo beta-thalassemia gene therapy.

The CDMO expanded GMP analytical capabilities, including in vitro bioequivalence testing, to support early-stage development of inhaled and nasal therapies.

The investment will expand production, warehousing, and quality capabilities at the company’s Hengoed facility to strengthen medicine supply across the UK and Europe.

The submission follows completion of aseptic process simulation validation batches conducted under the revised EU GMP Annex 1 requirements.

The expanded BioMaP consortium agreement supports commercial-scale domestic production of two critical pharmaceutical ingredients using biosynthesis.

The company launched two cGMP facilities in Irvine, California, supporting formulation development, clinical manufacturing, and commercial production of tablets and capsules.

The system is designed to support commercial production of amorphous solid dispersions used to improve the bioavailability of poorly soluble drug candidates.

The new facility at Flatiron Park in Boulder will support process development and analytical services adjacent to the company’s peptide API manufacturing site.

The rational-design cell line reportedly delivers up to three-fold productivity gains while maintaining stability across modalities and scale-up.

The technology uses a novel protease and affinity tagging approach to simplify downstream purification of complex biologics.

The partnership adds 10 GMP production lines and 350,000 liters of reactor capacity to support clinical- through commercial-scale active pharmaceutical ingredient supply.

The deal grants Earendil exclusive rights to WuXi’s payload-linker platform, combining AI-driven antibody discovery with integrated antibody-drug conjugate manufacturing.

The CDMO will present on process analytical technology, digital manufacturing, and real-time analytics as part of FDA’s CBER Advanced Manufacturing Seminar Series.

Ipsen invested in containment and transfer equipment at Quotient’s Pennsylvania facility to support ongoing commercial production of a highly potent therapy for an ultra-rare ...

The collaboration is designed to align GMP RNA production with cell processing to reduce technical handoffs, accelerate clinical timelines, and strengthen U.S. supply chain.

The 46,000-square-foot Denton, Texas facility, part of the company’s $23 billion investment to expand its U.S. operations, is expected to be operational in 2028.

The new 30,000-square-foot facility in Bengaluru is designed to help biopharma developers shorten timelines and improve process control across multiple biologic modalities.

The 78,000-square-foot Costa Mesa facility is designed to support programs from cell line development through tech transfer into cGMP manufacturing.

The certification includes renewal for its oral solid dosage facility and first-time EU GMP approval for its oral liquid manufacturing site.

Construction is set to begin in spring 2026, with the two facilities in North Chicago expected to be fully operational in 2029 and supported by 300 new hires.

The deal expands GSK’s access to Bora’s global network, including its oral solid dose site in Maple Grove, Minnesota.

The CRDMO’s hiring spree aims to meet rising global demand and support expanded active pharmaceutical ingredient capacity across its India and international sites.

The collaboration will support development and GMP manufacturing of the allogeneic TED-A9 cell therapy program.

The move expands early-phase bioconjugates development and manufacturing capabilities at its Oss, Netherlands site.

The 300,000-square-foot site in Richfield adds cleanroom capacity and 300 jobs to support high-volume pharmaceutical device manufacturing.

The CDMO’s Leganés facility expansion adds clinical and pilot-scale capacity for potent oral solid dose programs.

The collaboration supports clinical production and regulatory work for a CRISPR-edited GD2 CAR-T program targeting solid tumors.